Watch VCRT - Vicor Technologies

piccooar · 05-04-2009, 04:45 PM

Guys, I am an art dealer by day and have a client who turned me on to this stock and I now follow it on pure spec. I wanted to share some of the information with you and see what some general thoughts and feedback were. I've got tons of information and am not sure how/ or if I should post all of it but here's a bunch. Please ask for anything my rookie ass may have left out that would be helpful.

The general idea is that VCRT is an under-appreciated but exciting medical diagnostics company with a unique technology platform. They are in the process of commercializing several products based on their proprietary PD2i software. The PD2i enables physicians to accurately and easily risk stratify their patients by predicting future pathological outcomes, especially in the cardiovascular and trauma arena. They view the PD2i as a new Vital Sign that can provide critical information to a physician about a patient's status faster and easier than any other vital signs now being monitored.

INVESTOR HIGHLIGHTS:

The PD2i Analyzer was cleared for marketing by the FDA on December 29, 2008
Vicor expects to file a 510(k) application with the U.S. FDA, covering the PD2i
VS trauma indication in the first quarter of 2009, and anticipates clearance by the
third quarter of 2009 or sooner.
•
Vicor’s PD2i Cardiac Analyzer addresses a patient population of at least
12,000,000 and growing 5% annually.
•
Vicor’s PD2i Cardiac Analyzer is expected to garner European Union CE Mark
approval in the third quarter of 2009, and U.S. FDA 510(k) approval by the first
quarter of 2010 (if not sooner).
•
ICD’s are implanted to prevent SCD, yet studies show 75%+ are unnecessary,
creating a multi-billion dollar cost burden to the U.S. healthcare system.
•
Upon FDA clearance, Vicor’s revenues and profits could surge quickly due to the
medical need and ease of adoption of its developed medical products.
•
Vicor expects to file a 510(k) application with the U.S. FDA covering the PD2i
OR/ICU in the second quarter of 2009 with approval expected later in the year.
•
Vicor’s PD2i software is a platform for risk stratification that is potentially
applicable for use on any stream of biological data with applicability to other high
profile diseases such as Alzheimer’s Disease.
•
Vicor has a highly credentialed, experienced management team, which is
augmented by a world-renowned Scientific Advisory Board (SAB);
•
400 physicians, including more than 300 cardiologists, are shareholders in Vicor.

VicVan · 05-04-2009, 05:57 PM

Has my name in it - have to buy it
Nice detail - I take a look but its so odd vs my usual will buy something even if its a small tickle
cheers

piccooar · 05-04-2009, 07:24 PM

I've got all of the investor package information, as well as a couple of huge pdf files relating to the products and company. If you'd like to see any of it, let me know, will be happy to email.

josepaint · 05-08-2009, 01:55 AM

Hello there!

My first post here, great forum!

I am a VCRT shareholder and I absolutely love this stock. I bought at $,25, $.85, & $1.05.
Its the only stock I am currently holding and I'm waiting to take some profits (hopefully soon).

The technology platform PD2i, has multiple possible uses.

1. PD2i Analyzer
The ability to predict the onset of diabetes. The old ounce of prevention adage applies here.
Expected FDA approval coming this Q2 so any day now...... The test is non invasive fast and
easy. Should make this company very profitable very quickly.

2. PD2i Cardiac Analyzer
The ability to tell you if you will or will not have a massive heart attack, think Tim Russert,
within six months. The cost would be $300. Most patients don't make it to the ER. Which
insurance company/patient doesn't want that test. Also the ability to tell the makers of the
implantable defibulator who really needs it (they're having a hard time determining).

3. PD2i VS (Vital Sign)
The ability to triage a combat wounded soldier or ER patient quickly and effectively, thereby
allowing for the use of limited and expensive resources on the troop/ER patient who
desperately needs it.

These are the first three applications for this company. They are all due for commercialization this year. When this company becomes a profitable organization the current stock price will look like quite a bargain I believe.

A man named Michio Kaku, who is a well known Physicist wrote a book called "Visions" around a decade ago. It has turned out to be prophetic. In the book he said that the future of medicine will be about a deeper understanding of the human body. That will allow for less invasive, less costly, and gentler treatments. We will look back on things like chemotherapy the way we now look back on bleeding as a treatment. Barbaric.

Amazon.com: Visions: How Science Will Revolutionize the 21st Century: Michio Kaku: Books

Vicor has what looks like the key to that type of medical breakthrough treatments.

Happy Trading.

josepaint · 05-08-2009, 01:57 AM

Hello there!

My first post here, great forum!

I am a VCRT shareholder and I absolutely love this stock. I bought at $,25, $.85, & $1.05.
Its the only stock I am currently holding and I'm waiting to take some profits (hopefully soon).

The technology platform PD2i, has multiple possible uses.

1. PD2i Analyzer
The ability to predict the onset of diabetes. The old ounce of prevention adage applies here.
Expected FDA approval coming this Q2 so any day now...... The test is non invasive fast and
easy. Should make this company very profitable very quickly.

2. PD2i Cardiac Analyzer
The ability to tell you if you will or will not have a massive heart attack, think Tim Russert,
within six months. The cost would be $300. Most patients don't make it to the ER. Which
insurance company/patient doesn't want that test. Also the ability to tell the makers of the
implantable defibulator who really needs it (they're having a hard time determining).

3. PD2i VS (Vital Sign)
The ability to triage a combat wounded soldier or ER patient quickly and effectively, thereby
allowing for the use of limited and expensive resources on the troop/ER patient who
desperately needs it.

These are the first three applications for this company. They are all due for commercialization this year. When this company becomes a profitable organization the current stock price will look like quite a bargain I believe.

A man named Michio Kaku, who is a well known Physicist wrote a book called "Visions" around a decade ago. It has turned out to be prophetic. In the book he said that the future of medicine will be about a deeper understanding of the human body. That will allow for less invasive, less costly, and gentler treatments. We will look back on things like chemotherapy the way we now look back on bleeding as a treatment. Barbaric.

Amazon.com: Visions: How Science Will Revolutionize the 21st Century: Michio Kaku: Books

Vicor has what looks like the key to that type of medical breakthrough treatments.

Happy Trading.

OTCShowcase · 02-24-2011, 03:21 PM

Some companies just flutter around trying to strategize how to get operations rolling and others seem to have it all under control with continuously moving forward with operations, revenues and expansion. Vicor Technologies certainly qualifies as the latter of those two types. No catalyst is needed to keep the Company driving forward with advancements with their proprietary PD2i® technology. The groundwork was laid in the prior years and since expanding its sales force in the third quarter of 2010, Vicor has not been shy of announcements showcasing the growth of revenues and distribution.

On Wednesday, February 23rd, Vicor announced another significant move to broaden their footprint globally by signing a distribution agreement with Hadar Training and Medical Services to serve as its exclusive agent for marketing and sale of its PD2i Analyzer™, PD2i CA™(Cardiac Analyzer) and PD2i VS™ (Vital Sign) in Israel and Palestine. Operating since 1987, Hadar is an industry leader in providing first aid, resuscitation, EMT and Advanced Trauma Life Support (ATLS) as well as trauma training and medical programs. Hadar is also a leader in the importation and marketing of emergency medical equipment to community and field hospitals, and in the conversion and supply of mobile intensive care units and ambulances.

This new agreement is a perfect fit for Vicor and its revolutionary technology that has been dubbed “the new vital sign” given its propensity to accurately diagnose trauma patients and risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

Vicor CEO David Fater commented,

"We're extremely pleased to have HADAR representing our PD2i® products. Hadar is a leader in the importation and marketing of emergency medical equipment to the Israeli community and field hospitals. Hadar will obtain approval from the Israel Ministry of Health and any other required regulatory authorities for the marketing of our products at its expense. We are confident that Hadar will be successful in securing the necessary regulatory approvals for our products as quickly as possible and are excited by the prospect of having our PD2i® products made available throughout the Israeli emergency medical community.”

As mentioned, Vicor is motivated and expanding rapidly and doing it while keeping its share structure firmly intact. With only approximately 46 million shares outstanding and less than 37 million in the float, investors may soon be taking notice of the Company as the PD2i®-based products continue to be used worldwide; which could lead to future press releases along the lines of the one announced two weeks ago detailing revenues from January 2011 topping totals from the whole fourth quarter of 2010.

More information on Vicor Technologies and its PD2i® technologies can be found on the Company’s website at www.vicortech.com. Investors can learn more about Hadar Training and Medical Services www.hadar-medical.co.il/len/.

graycol · 02-28-2011, 05:01 PM

Press Release Source: Vicor Technologies, Inc. On Wednesday February 23, 2011, 8:30 am EST

BOCA RATON, FL--(Marketwire - 02/23/11) - David H. Fater, CEO of Vicor Technologies, Inc. (OTC.BB:VCRT - News), today announced the Company has entered into an agreement with Hadar Training and Medical Services to serve as its exclusive agent for the marketing and sale of its PD2i Analyzer™, PD2i CA™ (Cardiac Analyzer) and PD2i VS ™ (Vital Sign) in Israel and Palestine. Vicor Technologies (http://www.vicortech.com) is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, diabetics for the presence of diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

05-04-2009, 04:45 PM	#1
piccooar UberTrader Join Date: May 2009 Location: Fort Lauderdale, FL Posts: 150 Favorites: BIPH, CTIC, HEB Rep Power: 124 Reputation: 1688	VCRT - Vicor Technologies Guys, I am an art dealer by day and have a client who turned me on to this stock and I now follow it on pure spec. I wanted to share some of the information with you and see what some general thoughts and feedback were. I've got tons of information and am not sure how/ or if I should post all of it but here's a bunch. Please ask for anything my rookie ass may have left out that would be helpful. The general idea is that VCRT is an under-appreciated but exciting medical diagnostics company with a unique technology platform. They are in the process of commercializing several products based on their proprietary PD2i software. The PD2i enables physicians to accurately and easily risk stratify their patients by predicting future pathological outcomes, especially in the cardiovascular and trauma arena. They view the PD2i as a new Vital Sign that can provide critical information to a physician about a patient's status faster and easier than any other vital signs now being monitored. INVESTOR HIGHLIGHTS: The PD2i Analyzer was cleared for marketing by the FDA on December 29, 2008 Vicor expects to file a 510(k) application with the U.S. FDA, covering the PD2i VS trauma indication in the first quarter of 2009, and anticipates clearance by the third quarter of 2009 or sooner. • Vicor’s PD2i Cardiac Analyzer addresses a patient population of at least 12,000,000 and growing 5% annually. • Vicor’s PD2i Cardiac Analyzer is expected to garner European Union CE Mark approval in the third quarter of 2009, and U.S. FDA 510(k) approval by the first quarter of 2010 (if not sooner). • ICD’s are implanted to prevent SCD, yet studies show 75%+ are unnecessary, creating a multi-billion dollar cost burden to the U.S. healthcare system. • Upon FDA clearance, Vicor’s revenues and profits could surge quickly due to the medical need and ease of adoption of its developed medical products. • Vicor expects to file a 510(k) application with the U.S. FDA covering the PD2i OR/ICU in the second quarter of 2009 with approval expected later in the year. • Vicor’s PD2i software is a platform for risk stratification that is potentially applicable for use on any stream of biological data with applicability to other high profile diseases such as Alzheimer’s Disease. • Vicor has a highly credentialed, experienced management team, which is augmented by a world-renowned Scientific Advisory Board (SAB); • 400 physicians, including more than 300 cardiologists, are shareholders in Vicor. __________________ Sometimes you're flush and sometimes you're bust, and when you're up, it's never as good as it seems, and when you're down, you never think you'll be up again, BUT life goes on.
	1 thumbs up / 0 thumbs down. Rate this post \|

05-04-2009, 05:57 PM	#2
VicVan UberTrader Join Date: Apr 2009 Location: London Posts: 666 Favorites: ANTO, GE, XL Rep Power: 242 Reputation: 4102	Has my name in it - have to buy it Nice detail - I take a look but its so odd vs my usual will buy something even if its a small tickle cheers __________________ Always do your own research and make up your own mind on any stock. Top investors follow themselves, sheep get slaughtered. Any tip, suggestion or comment posted by me is simply a suggestion / prompt for you to make up your own mind. No liability will be accepted. Its not a professional view, its a suggestion. Shares go up and down. Always spread your investments, always set your stops both up and down. If shorting or Futures investing, know what your doing. You cant beat the sharks, but you can swim on their back. Trade lucky.
	Rate this post \|

05-04-2009, 07:24 PM	#3
piccooar UberTrader Join Date: May 2009 Location: Fort Lauderdale, FL Posts: 150 Favorites: BIPH, CTIC, HEB Rep Power: 124 Reputation: 1688	I've got all of the investor package information, as well as a couple of huge pdf files relating to the products and company. If you'd like to see any of it, let me know, will be happy to email. __________________ Sometimes you're flush and sometimes you're bust, and when you're up, it's never as good as it seems, and when you're down, you never think you'll be up again, BUT life goes on.
	Rate this post \|

05-08-2009, 01:55 AM	#4
josepaint Junior Trader Join Date: May 2009 Location: LOS ANGELES CALIFORNIA Posts: 2 Favorites: VCRT SRS SLW Rep Power: 51 Reputation: 10	Hello there! My first post here, great forum! I am a VCRT shareholder and I absolutely love this stock. I bought at $,25, $.85, & $1.05. Its the only stock I am currently holding and I'm waiting to take some profits (hopefully soon). The technology platform PD2i, has multiple possible uses. 1. PD2i Analyzer The ability to predict the onset of diabetes. The old ounce of prevention adage applies here. Expected FDA approval coming this Q2 so any day now...... The test is non invasive fast and easy. Should make this company very profitable very quickly. 2. PD2i Cardiac Analyzer The ability to tell you if you will or will not have a massive heart attack, think Tim Russert, within six months. The cost would be $300. Most patients don't make it to the ER. Which insurance company/patient doesn't want that test. Also the ability to tell the makers of the implantable defibulator who really needs it (they're having a hard time determining). 3. PD2i VS (Vital Sign) The ability to triage a combat wounded soldier or ER patient quickly and effectively, thereby allowing for the use of limited and expensive resources on the troop/ER patient who desperately needs it. These are the first three applications for this company. They are all due for commercialization this year. When this company becomes a profitable organization the current stock price will look like quite a bargain I believe. A man named Michio Kaku, who is a well known Physicist wrote a book called "Visions" around a decade ago. It has turned out to be prophetic. In the book he said that the future of medicine will be about a deeper understanding of the human body. That will allow for less invasive, less costly, and gentler treatments. We will look back on things like chemotherapy the way we now look back on bleeding as a treatment. Barbaric. Amazon.com: Visions: How Science Will Revolutionize the 21st Century: Michio Kaku: Books Amazon.com: Visions: How Science Will Revolutionize the 21st Century: Michio Kaku: Books Vicor has what looks like the key to that type of medical breakthrough treatments. Happy Trading.
	Rate this post \|

05-08-2009, 01:57 AM	#5
josepaint Junior Trader Join Date: May 2009 Location: LOS ANGELES CALIFORNIA Posts: 2 Favorites: VCRT SRS SLW Rep Power: 51 Reputation: 10	Hello there! My first post here, great forum! I am a VCRT shareholder and I absolutely love this stock. I bought at $,25, $.85, & $1.05. Its the only stock I am currently holding and I'm waiting to take some profits (hopefully soon). The technology platform PD2i, has multiple possible uses. 1. PD2i Analyzer The ability to predict the onset of diabetes. The old ounce of prevention adage applies here. Expected FDA approval coming this Q2 so any day now...... The test is non invasive fast and easy. Should make this company very profitable very quickly. 2. PD2i Cardiac Analyzer The ability to tell you if you will or will not have a massive heart attack, think Tim Russert, within six months. The cost would be $300. Most patients don't make it to the ER. Which insurance company/patient doesn't want that test. Also the ability to tell the makers of the implantable defibulator who really needs it (they're having a hard time determining). 3. PD2i VS (Vital Sign) The ability to triage a combat wounded soldier or ER patient quickly and effectively, thereby allowing for the use of limited and expensive resources on the troop/ER patient who desperately needs it. These are the first three applications for this company. They are all due for commercialization this year. When this company becomes a profitable organization the current stock price will look like quite a bargain I believe. A man named Michio Kaku, who is a well known Physicist wrote a book called "Visions" around a decade ago. It has turned out to be prophetic. In the book he said that the future of medicine will be about a deeper understanding of the human body. That will allow for less invasive, less costly, and gentler treatments. We will look back on things like chemotherapy the way we now look back on bleeding as a treatment. Barbaric. Amazon.com: Visions: How Science Will Revolutionize the 21st Century: Michio Kaku: Books Amazon.com: Visions: How Science Will Revolutionize the 21st Century: Michio Kaku: Books Vicor has what looks like the key to that type of medical breakthrough treatments. Happy Trading.
	Rate this post \|

02-24-2011, 03:21 PM	#6
OTCShowcase Junior Trader Join Date: Jul 2010 Location: KY Posts: 6 Favorites: CTIX, NLEF, ALRT Rep Power: 36 Reputation: 10	Vicor Continues Expansion; Signs Distribution Agreement in Middle East Some companies just flutter around trying to strategize how to get operations rolling and others seem to have it all under control with continuously moving forward with operations, revenues and expansion. Vicor Technologies certainly qualifies as the latter of those two types. No catalyst is needed to keep the Company driving forward with advancements with their proprietary PD2i® technology. The groundwork was laid in the prior years and since expanding its sales force in the third quarter of 2010, Vicor has not been shy of announcements showcasing the growth of revenues and distribution. On Wednesday, February 23rd, Vicor announced another significant move to broaden their footprint globally by signing a distribution agreement with Hadar Training and Medical Services to serve as its exclusive agent for marketing and sale of its PD2i Analyzer™, PD2i CA™(Cardiac Analyzer) and PD2i VS™ (Vital Sign) in Israel and Palestine. Operating since 1987, Hadar is an industry leader in providing first aid, resuscitation, EMT and Advanced Trauma Life Support (ATLS) as well as trauma training and medical programs. Hadar is also a leader in the importation and marketing of emergency medical equipment to community and field hospitals, and in the conversion and supply of mobile intensive care units and ambulances. This new agreement is a perfect fit for Vicor and its revolutionary technology that has been dubbed “the new vital sign” given its propensity to accurately diagnose trauma patients and risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention. Vicor CEO David Fater commented, "We're extremely pleased to have HADAR representing our PD2i® products. Hadar is a leader in the importation and marketing of emergency medical equipment to the Israeli community and field hospitals. Hadar will obtain approval from the Israel Ministry of Health and any other required regulatory authorities for the marketing of our products at its expense. We are confident that Hadar will be successful in securing the necessary regulatory approvals for our products as quickly as possible and are excited by the prospect of having our PD2i® products made available throughout the Israeli emergency medical community.” As mentioned, Vicor is motivated and expanding rapidly and doing it while keeping its share structure firmly intact. With only approximately 46 million shares outstanding and less than 37 million in the float, investors may soon be taking notice of the Company as the PD2i®-based products continue to be used worldwide; which could lead to future press releases along the lines of the one announced two weeks ago detailing revenues from January 2011 topping totals from the whole fourth quarter of 2010. More information on Vicor Technologies and its PD2i® technologies can be found on the Company’s website at www.vicortech.com. Investors can learn more about Hadar Training and Medical Services www.hadar-medical.co.il/len/.
	Rate this post \|

Thread Tools	Search this Thread
Show Printable Version Email this Page	Search this Thread: Advanced Search